Hearing loss trial of GenVec gene therapy clears hurdle

GenVec Inc. (NASDAQ:GNVC) rose $0.02 to $0.80 on Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN)

Read the full 153 word article

User Sign In